Drug

Elebsiran clinical trials

Also written VIR-2218.

studies test it: 12
open now: 1
in phase 3: 1
first study started: 2018

Keep track of what changes. Save the elebsiran studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

12 studies that test it; most in 2023 (3)

Studies that test elebsiran, by start year
Year	Studies
2018	1
2020	1
2021	1
2022	2
2023	3
2024	2
2025	2

By phase

A phase 1/2 study counts in both.

Phase 1: 5
Phase 2: 8
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it.

Hepatitis B, Chronic: 7
Hepatitis D, Chronic: 1
Hepatitis: 1
Fibrosis: 1

Who runs them

Industry 11 · Other 1

Vir Biotechnology, Inc. (7) · Brii Biosciences Limited (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Virion Therapeutics (1)

Often tested with

Tested in the same studies.

Tobevibart (4) · BRII-179 (2) · Peginterferon alfa-2a (1) · Pegylated Interferon Alfa (1) · VRON-0200 (1)

Studies

Open first, then newest update. How each study uses elebsiran is read from its arms, and is right about nine times in ten.

Testing it · 12

Given in every arm · 5 — elebsiran is usual care beside what is tested

Codes

What other systems call elebsiran · ClinicalTrials.gg INT018332

UNII (FDA) W982Y6N4X7ELEBSIRANOne source FDA
NCI Thesaurus C190492ElebsiranOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	W982Y6N4X7	ELEBSIRAN	One source FDA
NCI Thesaurus	C190492	Elebsiran	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.